TNF-alpha and Inflammation
TNF-alpha has been shown to play an important role in the pathogenesis of diseases like rheumatoid arthritis (RA), and inflammatory bowel disease (IBD) (i.e., Crohn's disease and ulcerative colitis).
Current therapies use antibodies that inhibit the effect of TNF-alpha in RA and IBD to bind to targets in the extracellular space on the outside of the cell.
Our novel proprietary anti-TNF-alpha therapeutic inhibitor is designed to bind TNF-alpha within the cytoplasm of the cell and block it from being released into the extracellular space. We have several anti-TNF-alpha inhibitors that are in preclinical development.
Intracellular proteins are inaccessible to larger biologic molecules, such as traditional monoclonal antibodies and pharmaceutical compounds.
However, we can target and inhibit the functions of these intracellular proteins because our therapeutic agents are ‘small’ enough in size to enter the cells.
After gaining this developmental success, we are now ready to move into the pre-IND phase of development.